Patents by Inventor Max D. Cooper

Max D. Cooper has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11945857
    Abstract: Disclosed are compositions and methods related to variable lymphocyte receptors (VLRs). More particularly, disclosed are a variety of antigen specific polypeptides, including soluble, monoclonal, and multivalent forms, as well as methods of using the polypeptides, antibodies that bind the antigen specific polypeptides, and nucleic acids, vectors and expression systems that encode the polypeptides. Antigen specific polypeptides that selectively bind pathogens, like anthrax, and carbohydrates, like blood group determinants, are specifically disclosed.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: April 2, 2024
    Assignee: THE UAB RESEARCH FOUNDATION
    Inventors: Max D. Cooper, Brantley R. Herrin, Matthew N. Alder
  • Publication number: 20210253676
    Abstract: Disclosed are compositions and methods related to variable lymphocyte receptors (VLRs). More particularly, disclosed are a variety of antigen specific polypeptides, including soluble, monoclonal, and multivalent forms, as well as methods of using the polypeptides, antibodies that bind the antigen specific polypeptides, and nucleic acids, vectors and expression systems that encode the polypeptides. Antigen specific polypeptides that selectively bind pathogens, like anthrax, and carbohydrates, like blood group determinants, are specifically disclosed.
    Type: Application
    Filed: December 18, 2020
    Publication date: August 19, 2021
    Applicant: THE UAB RESEARCH FOUNDATION
    Inventors: Max D. Cooper, Brantley R. Herrin, Matthew N. Alder
  • Patent number: 10870692
    Abstract: Disclosed are compositions and methods related to variable lymphocyte receptors (VLRs). More particularly, disclosed are a variety of antigen specific polypeptides, including soluble, monoclonal, and multivalent forms, as well as methods of using the polypeptides, antibodies that bind the antigen specific polypeptides, and nucleic acids, vectors and expression systems that encode the polypeptides. Antigen specific polypeptides that selectively bind pathogens, like anthrax, and carbohydrates, like blood group determinants, are specifically disclosed.
    Type: Grant
    Filed: February 1, 2019
    Date of Patent: December 22, 2020
    Assignee: THE UAB RESEARCH FOUNDATION
    Inventors: Max D. Cooper, Brantley R. Herrin, Matthew N. Alder
  • Publication number: 20190202897
    Abstract: Disclosed are compositions and methods related to variable lymphocyte receptors (VLRs). More particularly, disclosed are a variety of antigen specific polypeptides, including soluble, monoclonal, and multivalent forms, as well as methods of using the polypeptides, antibodies that bind the antigen specific polypeptides, and nucleic acids, vectors and expression systems that encode the polypeptides. Antigen specific polypeptides that selectively bind pathogens, like anthrax, and carbohydrates, like blood group determinants, are specifically disclosed.
    Type: Application
    Filed: February 1, 2019
    Publication date: July 4, 2019
    Inventors: Max D. Cooper, Brantley R. Herrin, Matthew N. Alder
  • Patent number: 10239936
    Abstract: Disclosed are compositions and methods related to variable lymphocyte receptors (VLRs). More particularly, disclosed are a variety of antigen specific polypeptides, including soluble, monoclonal, and multivalent forms, as well as methods of using the polypeptides, antibodies that bind the antigen specific polypeptides, and nucleic acids, vectors and expression systems that encode the polypeptides. Antigen specific polypeptides that selectively bind pathogens, like anthrax, and carbohydrates, like blood group determinants, are specifically disclosed.
    Type: Grant
    Filed: February 25, 2016
    Date of Patent: March 26, 2019
    Assignee: The UAB Research Foundation
    Inventors: Max D. Cooper, Brantley R. Herrin, Matthew N. Alder
  • Publication number: 20160376348
    Abstract: Disclosed are compositions and methods related to variable lymphocyte receptors (VLRs). More particularly, disclosed are a variety of antigen specific polypeptides, including soluble, monoclonal, and multivalent forms, as well as methods of using the polypeptides, antibodies that bind the antigen specific polypeptides, and nucleic acids, vectors and expression systems that encode the polypeptides. Antigen specific polypeptides that selectively bind pathogens, like anthrax, and carbohydrates, like blood group determinants, are specifically disclosed.
    Type: Application
    Filed: February 25, 2016
    Publication date: December 29, 2016
    Inventors: Max D. Cooper, Brantley R. Herrin, Matthew N. Alder
  • Patent number: 8648171
    Abstract: The invention relates to members of the Fc receptor homolog (FcRH) subfamily, as well as fragments and variants thereof. Each FcRH is a Type I transmembrane receptor, preferably, comprises an extracellular region, a transmembrane region, and a cytoplasmic region. The cytoplasmic region preferably comprises one or more immunoreceptor tyrosine-based inhibitory or activation motifs (“ITIMs” or “ITAMs). The invention provides polypeptides, nucleic acids, vectors, expression systems, and antibodies and antibody fragments related to the FcRHs as well as uses thereof. Such uses include uses in the diagnosis and treatment of a malignancy of hematopoietic cell lineage or an inflammatory or autoimmune disease in a subject and in the modulation of a humoral immune response in a subject.
    Type: Grant
    Filed: August 7, 2007
    Date of Patent: February 11, 2014
    Assignee: The UAB Research Foundation
    Inventors: Randall S. Davis, Max D. Cooper
  • Publication number: 20120189640
    Abstract: Disclosed are compositions and methods related to variable lymphocyte receptors (VLRs). More particularly, disclosed are a variety of antigen specific polypeptides, including soluble, monoclonal, and multivalent forms, as well as methods of using the polypeptides, antibodies that bind the antigen specific polypeptides, and nucleic acids, vectors and expression systems that encode the polypeptides. Antigen specific polypeptides that selectively bind pathogens, like anthrax, and carbohydrates, like blood group determinants, are specifically disclosed.
    Type: Application
    Filed: July 27, 2007
    Publication date: July 26, 2012
    Applicant: THE UAB RESEARCH FOUNDATION
    Inventors: Max D. Cooper, Brantley R. Herrin, Matthew N. Alder
  • Patent number: 8212018
    Abstract: Disclosed are compositions and methods related to variable lymphocyte receptors (VLRs).
    Type: Grant
    Filed: September 9, 2011
    Date of Patent: July 3, 2012
    Assignee: The UAB Research Foundation
    Inventors: Zeev Pancer, Max D. Cooper, Chris Amemiya, G. Larry Gartland, Goetz R. A. Ehrhardt
  • Publication number: 20120107929
    Abstract: Disclosed are compositions and methods related to variable lymphocyte receptors (VLRs).
    Type: Application
    Filed: September 9, 2011
    Publication date: May 3, 2012
    Applicants: BENAROYA RESEARCH INSTITUTE, THE UAB RESEARCH FOUNDATION
    Inventors: Zeev Pancer, Max D. Cooper, Chris Amemiya, G. Larry Gartland, Goetz R. A. Ehrhardt
  • Patent number: 8039588
    Abstract: Disclosed are compositions and methods related to variable lymphocyte receptors (VLRs).
    Type: Grant
    Filed: May 23, 2005
    Date of Patent: October 18, 2011
    Assignees: The UAB Research Foundation, Benaroya Research Institute
    Inventors: Zeev Pancer, Max D. Cooper, Chris Amemiya, G. Larry Gartland, Goetz R. A. Ehrhardt
  • Publication number: 20110165584
    Abstract: Disclosed are compositions and methods related to variable lymphocyte receptors (VLRs).
    Type: Application
    Filed: May 23, 2005
    Publication date: July 7, 2011
    Applicants: UAB RESEARCH FOUNDATION, THE, BENAROYA RESEARCH INSTITUTE
    Inventors: Zeev Pancer, Max D. Cooper, Chris Amemiya, G. Larry Gartland, Goetz R. A. Ehrhardt
  • Publication number: 20110086047
    Abstract: Provided herein are antibodies having the same epitope specificity as an antibody produced by the hybridoma cell line deposited with the American Type Culture Collection as hybridoma 4-2A6, 1-5A3, or 1-3B4. Further provided herein are methods of identifying and selecting cells that express FcRH1 or FcRH4. Methods of diagnosing and treating a subject with a malignancy of a hematopoietic cell lineage or an autoimmune disease and methods of modulating a humoral immune response in a subject are also provided herein. Further provided herein are polypeptides comprising one or more complementary determining regions of the disclosed antibodies and nucleic acids that encode the disclosed polypeptides.
    Type: Application
    Filed: May 13, 2010
    Publication date: April 14, 2011
    Applicant: THE UAB RESEARCH FOUNDATION
    Inventors: Randall S. Davis, Max D. Cooper, Chuen-Miin Leu, Goetz R. A. Ehrhardt
  • Publication number: 20080131433
    Abstract: Provided herein are antibodies having the same epitope specificity as an antibody produced by the hybridoma cell line deposited with the American Type Culture Collection as hybridoma 4-2A6, 1-5A3, or 1-3B4. Further provided herein are methods of identifying and selecting cells that express FcRH1 or FcRH4. Methods of diagnosing and treating a subject with a malignancy of a hematopoietic cell lineage or an autoimmune disease and methods of modulating a humoral immune response in a subject are also provided herein. Further provided herein are polypeptides comprising one or more complementary determining regions of the disclosed antibodies and nucleic acids that encode the disclosed polypeptides.
    Type: Application
    Filed: September 27, 2005
    Publication date: June 5, 2008
    Applicant: THE UAB RESEARCH FOUNDATION
    Inventors: Randall S. Davis, Max D. Cooper, Chuen-Miin Leu, Goetz R. Ehrhardt
  • Patent number: 7317087
    Abstract: The invention relates to members of the Fc receptor homolog (FcRH) subfamily, as well as fragments and variants thereof. Each FcRH is a Type I transmembrane receptor, preferably, comprises an extracellular region, a transmembrane region, and a cytoplasmic region. The cytoplasmic region preferably comprises one or more immunoreceptor tyrosine-based inhibitory or activation motifs (“ITIMs” or “ITAMs). The invention provides polypeptides, nucleic acids, vectors, expression systems, and antibodies and antibody fragments related to the FcRHs as well as uses thereof. Such uses include uses in the diagnosis and treatment of a malignancy of hematopoietic cell lineage or an inflammatory or autoimmune disease in a subject and in the modulation of a humoral immune response in a subject.
    Type: Grant
    Filed: March 25, 2003
    Date of Patent: January 8, 2008
    Assignee: The UAB Research Foundation
    Inventors: Randall S. Davis, Max D. Cooper